Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

Fig. 3

Correlation of changes in ApoB100 with non-HDL-C, remnant cholesterol and TGs. The X axis represents changes in ApoB100 from baseline to the mean of weeks 10 and 12 in evolocumab-treated patients; the Y axis represents changes in non-HDL-C, TGs or remnant cholesterol from baseline to the mean of weeks 10 and 12 in evolocumab-treated patients. All correlation coefficients are statistically significant at P < 0.0001. ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, TG triglycerides

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840